G
Gideon Koren
Researcher at Ariel University
Publications - 2007
Citations - 88165
Gideon Koren is an academic researcher from Ariel University. The author has contributed to research in topics: Pregnancy & Population. The author has an hindex of 129, co-authored 1994 publications receiving 81718 citations. Previous affiliations of Gideon Koren include McGill University Health Centre & University of Western Ontario.
Papers
More filters
Journal ArticleDOI
Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis
TL;DR: There was no association between first-trimester exposure to sex hormones generally (or to OCs specifically) and external genital malformations, and women exposed to sex hormone after conception may be assured there is no increased risk of fetal sexual malformation.
Journal ArticleDOI
Nonsteroidal Antiinflammatory Drugs During Third Trimester and the Risk of Premature Closure of the Ductus Arteriosus: A Meta-Analysis
TL;DR: Short-term use of NSAIDs in late pregnancy is associated with a significant increase in the risk of premature ductal closure, particularly in women exposed to indomethacin.
Journal ArticleDOI
Antioxidants and fetal protection against ethanol teratogenicity. I. Review of the experimental data and implications to humans.
Raanan Cohen-Kerem,Gideon Koren +1 more
TL;DR: In this paper, the authors reviewed the data of antioxidant effects in experimental models of fetal alcohol syndrome and concluded that the application of a treatment strategy that includes antioxidants is justified since antioxidant treatment in human pregnancy for pre-eclampsia was demonstrated to be safe and effective.
Journal ArticleDOI
Pregnancy outcome of women exposed to azathioprine during pregnancy.
Lee H. Goldstein,Galit Dolinsky,Revital Greenberg,Christof Schaefer,Raanan Cohen-Kerem,Orna Diav-Citrin,Heli Malm,Minke. E. Reuvers-Lodewijks,Margreet M. Rost van Tonningen-van Driel,Judith Arnon,Asher Ornoy,Maurizio Clementi,Elena Di Gianantonio,Gideon Koren,Rony Braunstein,Matitiahu Berkovitch +15 more
TL;DR: It is suggested that AZP (50-100 mg/day) does not triple the rate of birth defects; however, it is associated with lower birth weight, gestational age, and prematurity.
Journal ArticleDOI
Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP).
TL;DR: Many medications, particularly H(1)-antagonists and phenothiazines, are safe and effective for treatment of varying degrees of NVP.